You are here

Portable Bioprinted Organoids for Physiological Monitoring

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA8650-19-P-6095
Agency Tracking Number: F19A-002-0136
Amount: $149,984.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: AF19A-T002
Solicitation Number: 19.A
Solicitation Year: 2019
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-07-31
Award End Date (Contract End Date): 2020-07-31
Small Business Information
701 McMillian Way NW Suite D
Huntsville, AL 35806
United States
DUNS: 185169620
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Kevin D Roehm
 Research Scientist
 (256) 726-4800
Business Contact
 Tanu Singhal
Phone: (256) 726-4800
Research Institution
 The Geneva Foundation
 Linzie Wagner Linzie Wagner
917 Pacific Ave, Suite 600
Tacoma, WA 98402
United States

 (253) 682-3809
 Domestic Nonprofit Research Organization

hazardous chemicals such as JP8, chromium, and byproducts of led-free frangible ammunition and to hazardous environments. Of the many dangers Airmen face, the hypoxia-like unexplained physiological events pilots face are some of the most dangerous and elusive. Current wearable sensors cannot decouple complex, interdependent in vivo response. We propose to develop (design, fabricate, test, and demonstrate) bioprinted organoids that recapitulates human-level architectures, and has integrated optical and impedance sensors that can monitor physiological markers. During Phase I, we will demonstrate proof-of-concept organoids and electrical sensors for functional, cell-based detection of hypoxia in a vascular and neural model. Organoid viability will be evaluated and functionality will be evaluated both with designed sensors and standard analytic techniques for both normoxia and hypoxia. In Phase II, organoids will be further developed. A small, portable bioreactor will also be developed integrating the organoids and sensors with means for environmental exposure while maintaining the organoids at otherwise physiological conditions. The developed platform will be validated in the laboratory and in potentially hazardous environments and commercialization efforts will be started

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government